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ABSTRACT 
Spectroscopic methods have already been used as effective tools in several studies involving the detection of 
cancer. Fourier transform infrared spectroscopy (FTIR) has already been applied in the discrimination of cancer 
cells and tissues or blood of patients with the disease, observing that this technique requires the use of 
chemometric algorithms to obtain such results. The aim of this study was to employ a partial least squares 
discriminant analysis (PLS-DA) with FTIR data in the discrimination of plasma samples from patients with 
colorectal cancer (CRC) and healthy individuals of both genders. Multivariate analysis was performed using PLS-
DA of the sample triplicates (n=90) with different types of processing. The best PLS-DA condition was obtained 
using the 1st derivative, 1 orthogonal signal correction (OSC) and no pre-processing. With 4 latent variables (LV), 
the model presented a root mean square error of cross-validation (RMSECV) of 0.0004 and coefficient of 
determination (r2) of 1.0000. The accuracy, precision and sensitivity of the model were 100%. This work 
presented an innovative methodology in which the differentiation between healthy and primary CRC patients was 
done directly from the plasma using non-invasive, fast, simple and low-cost technologies. 
DISCRIMINAÇÃO DE PACIENTES HÍGIDOS E COM CÂNCER COLORRETAL UTILIZANDO 
ESPECTROSCOPIA NO INFRAVERMELHO COM TRANSFORMADA DE FOURIER E QUIMIOMETRIA 
PALAVRAS CHAVE: FTIR. Câncer colorretal. PLS-DA. Quimiometria. 
RESUMO 
Métodos espectroscópicos já foram empregados como ferramentas eficientes em diversos estudos envolvendo a 
detecção de câncer. A espectroscopia no infravermelho com transformada de Fourier (FTIR) já foi aplicada na 
discriminação de células e tecidos cancerígenos ou sangue de portadores da doença, sendo que o emprego 
dessa técnica requer o uso de algoritmos quimiométricos para obtenção de tais resultados. O objetivo deste 
estudo foi empregar a análise discriminante com calibração multivariada por mínimos quadrados parciais (PLS-
DA) com dados de FTIR na discriminação de amostras de plasma de portadores de câncer colorretal (CCR) e 
indivíduos saudáveis de ambos os sexos. A análise multivariada foi realizada através da PLS-DA das triplicatas 
das amostras (n=90) com diferentes tipos de processamentos. A melhor condição de PLS-DA foi obtida 
utilizando-se a 1ª derivada, 1 correção ortogonal de sinal (OSC) e nenhum pré-processamento. Com 4 variáveis 
latentes, o modelo apresentou erro quadrático médio de validação cruzada (RMSECV) de 0,0016 e coeficiente de 
determinação (r2) de 0,9999. A acurácia, precisão e sensibilidade do modelo foram de 100%. Este trabalho 
apresentou uma metodologia inovadora na qual a diferenciação entre pacientes saudáveis e com CCR primário 
foi feita diretamente do plasma, utilizando tecnologias não invasivas, rápidas, simples e de baixo custo. 
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1 INTRODUCTION 
 
Cancer is one of the most frequent diseases of the 21st century. Colorectal cancer (CRC), specifically, is 
the third cancer of higher incidence and the second in mortality (BRAY et al., 2018; SIEGEL et al., 2017). However, 
the techniques used in its diagnosis are not always sensitive enough to do so, especially in the early stages, and 
many of them are quite invasive (STRUM, 2016). Instead of conventional biopsy, the use of liquid biopsies for the 
diagnosis and follow-up of the disease has been suggested, since they are not invasive. Various body fluids can be 
used with this purpose, such as plasma, serum and urine (CREE, 2015; HEITZER; ULZ; GEIGL, 2015; WANG et al., 
2017). 
In liquid biopsies, disease-specific biomarkers and their progression can be monitored. Among the 
several biomarkers, cell-free circulating DNA (BHANGU et al., 2017; BOYSEN et al., 2017; PEREIRA et al., 2017; 
SCHWARZENBACH; HOON; PANTEL, 2011), circulating tumor DNA (ALIX-PANABIÈRES; PANTEL, 2016; 
BETTEGOWDA et al., 2014; DIAZ JR; BARDELLI, 2014; HEITZER; ULZ; GEIGL, 2015) and some proteins 
(BETTEGOWDA et al., 2014; GAUTAM et al., 2012; PAN et al., 2011; REYNÉS et al., 2011) can be highlighted. 
However, some of these biomarkers have not yet been validated for use in clinical practice due to great variability 
among individuals, low sensitivity and specificity of the tests, lack of standardization of the procedures and pre-
analytical conditions and the high cost (EL MESSAOUDI et al., 2013; HEITZER; ULZ; GEIGL, 2015; 
SCHWARZENBACH; HOON; PANTEL, 2011). 
Fourier transform infrared (FTIR) spectroscopy has great potential as a health tool because it is 
relatively simple, low cost, noninvasive, nondestructive, reproducible and uses small amounts of sample with 
minimum preparation (MIKKONEN et al., 2016; MOVASAGHI; REHMAN; UR REHMAN, 2008; SIMSEK OZEK et al., 
2016; XIANG et al., 2010). FTIR associated with chemometrics allows the analysis of discrete biochemical 
changes related to a pathological state. Several neoplasms have already been detected using FTIR and 
multivariate calibration methods (CHABER et al., 2018; GAJJAR et al., 2013; HANDS et al., 2016; OLD et al, 2014; 
OLLESCH et al., 2014;) and, for CRC, mostly using solid (SAHU; MORDECHAI, 2010) and eventually liquid biopsies 
(KHANMOHAMMADI et al., 2007). Such studies are supported by the use of chemometric algorithms of 
classification as Linear Discriminant Analysis (LDA) (KHANMOHAMMADI et al., 2007) and Soft Independent 
Modeling by Class Analogy (SIMCA) (KHANMOHAMMADI et al., 2009). On the other hand, the use of Discriminant 
Analysis with Multivariate Partial Least Squares Calibration (PLS-DA) has been shown to be a better performance 
tool for discrimination of CRC biopsies using Raman spectroscopy (BERGHOLT et al., 2015; BERGHOLT et al., 
2016; LIU et al., 2016), but its applicability in the detection of patients with CRC in liquid samples using FTIR has 
not yet been evaluated. Liquid biopsies (blood, plasma) are easier to collect and analyze than solid biopsies and 
FTIR is often easier to implement in laboratory routines. In this sense, the aim of this study was to evaluate the 
use of the Attenuated Total Reflection (ATR-FTIR) technique in association with PLS-DA for discrimination of 
plasma samples from colorectal cancer patients and healthy individuals. 
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2 THEORETICAL FUNDAMENTALS 
 
2.1 COLORRETAL CANCER: INCIDENCE, CHARACTERISTICS AND DIAGNOSIS 
 
CRC is a type of malignant neoplasm that affects the colon (the longest part of the large intestine, 
between the cecum and rectum) and the rectum (the final portion of the large intestine before the anus). Like 
other malignancies, the development of CRC is a multi-step process involving genetic mutations in intestinal 
mucosal cells, activation of oncogenes (tumor-promoting genes), and loss or mutation of tumor suppressor genes 
(BOYLE; LEON, 2002; VOGELSTEIN et al., 1988). Most cases of CRC are derived from benign adenomatous polyps, 
or adenomas, abnormal growths of intestinal wall epithelial cells (BOYLE; LEON, 2002; STRUM, 2016). Few risk 
factors of non-dietary origin have been established for this neoplasm (e.g. inflammatory bowel diseases), most of 
which are associated with the individual's lifestyle and diet (BOYLE; LEON, 2002; HUNCHAREK; MUSCAT; 
KUPELNICK, 2008; PARK et al., 2005).  
CRC is the third cancer with the highest incidence and the second in mortality worldwide. More than 1.8 
million new cases and 881,000 deaths were estimated for 2018, representing 1 in 10 cases and cancer deaths 
for both genres (BRAY et al., 2018). When CRC is treated in the early stages, the chance of a favorable outcome is 
substantially increased compared to the disease in more advanced stages. In this sense, preventive actions are of 
great importance for the improvement of disease outcomes as well as reducing the mortality. Routine laboratory 
tests, such as fecal occult blood, have shown good results in reducing mortality associated with this disease 
(BAILEY; AGGARWAL; IMPERIALE, 2016; BÉNARD et al., 2018; HARDCASTLE et al., 1996; MANDEL et al., 1993; 
VENTURA et al., 2014). 
Among the tests available for the detection of the disease are colonoscopy, CT scan colonography, 
sigmoidoscopy, barium enema, fecal occult blood (guaiac-based and immunochemical), and DNA in feces. 
However, these tests present some disadvantages, especially regarding cost and sensitivity, and some are 
considered to be quite invasive, such as colonoscopy (STRUM, 2016). Patients’ acceptance of more invasive tests 
is an important factor to consider in the prevention of CRC. Patients' pain and discomfort before, during, and after 
procedures and need for sedatives and analgesics may decrease the acceptability of these exams by patients 
(SVENSSON et al., 2002; USSUI, 2010; USSUI et al., 2013). 
 
2.2 LIQUID BIOPSIES AND TUMOR BIOMARKERS 
 
Noninvasive tumor screening and diagnosis are a challenge in clinical practice. Tumors are very 
heterogeneous and the collected sample is not always representative enough. In addition, the biopsy makes it 
difficult to monitor tumor dynamics closely (CHAN et al., 2013; CREE, 2015; CROWLEY et al., 2013; HEITZER; ULZ; 
GEIGL, 2015). The concept of liquid biopsies has gained importance due to its potential in solving such 
"problems". Liquid biopsy refers to the use of body fluids, such as blood and urine, to diagnose and monitor 
cancers (or other conditions) through specific biomarkers (CROWLEY et al., 2013; WANG et al., 2017). 
DNA-free fragments of tumor origin can be found in the plasma, serum or urine of an individual, and are 
known as circulating tumor DNA (ctDNA) (CRISTOFANILLI et al., 2004; WANG et al., 2017). The ctDNA derives 
from tumor masses that release these fragments due to cell death and signaling and bring information of great 
relevance about the tumor and its dynamics and genetic characteristics (AL-NEDAWI et al., 2008; CHENG; SU; 
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QIAN, 2016; HENCH; HENCH; TOLNAY, 2018; VALADI et al., 2007; ZHANG et al., 2019). Several studies 
demonstrate the potential of ctDNA as prognosis and diagnosis biomarkers (CHENG; SU; QIAN, 2016; COHEN et 
al., 2008; CRISTOFANILLI et al., 2004; DE BONO et al., 2008), including early stage cancers (ALIX-PANABIÈRES; 
PANTEL, 2016; BETTEGOWDA et al., 2014; DAWSON et al., 2013; RHIM et al., 2012). Specific tumor-related 
mutations can be identified directly in plasma or serum of a patient, such as KRAS (acts in cell signaling and 
proliferation) (THIERRY et al., 2014; WANG et al., 2004), TP53 (acts on cell cycle control and apoptosis) 
(ARMAGHANY et al., 2012; LANE; BENCHIMOL, 1990; VOGELSTEIN et al., 1988; WANG et al., 2004) and EGFR 
(acts in cell signaling) (DIAZ JR et al., 2012; MOHAN et al., 2014) gene mutations. However, some of these 
biomarkers have not yet been validated for use in routines of this nature due to the great variability among 
individuals, low sensitivity and specificity of the tests, lack of standardization of procedures and pre-analytical 
conditions and high cost (EL MESSAOUDI et al., 2013; SCHWARZENBACH; HOON; PANTEL, 2011; WANG et al., 
2017).  
Other biomolecules have also shown potential as cancer biomarkers. Studies report changes in the free 
amino acid profile in plasma of cancer patients and among patients with different types of cancer (CASCINO et 
al., 1995; DEJONG et al., 2005; HEBER; BYERLY; CHLEBOWSKI, 1985; KUBOTA; MEGUID; HITCH, 1992; LAI et al., 
2005; MIYAGI et al., 2011; NORTON et al., 1985; PROENZA et al., 2003), even in early stages of the disease 
(MIYAGI et al., 2011). Variations in concentration and protein profile in cancer patients have also been 
demonstrated (ABRAMSON, 1982; GAUTAM et al., 2012; HANASH; PITTERI; FACA, 2008; PAN et al., 2011). 
Reynés et al. (2011) observed the elevation in the concentration of various inflammatory proteins, coagulation 
and angiogenesis factors in the plasma of glioblastoma patients, associated with the onset and development of 
cancers. 
It is important to emphasize that, because of tumor heterogeneity, biomarkers may vary during their 
progression and/or treatment (CHAN et al., 2013; CREE, 2015; CROWLEY et al., 2013). Thus, the analysis of 
biomarkers at different times can provide important information for disease follow-up, such as monitoring the 
patient's response to a certain treatment (HEITZER; ULZ; GEIGL, 2015; WANG et al., 2017). In order to effectively 
implement it into clinical practice, it will be necessary to develop rapid, sensitive and cost-effective methods 
(HEITZER; ULZ; GEIGL, 2015). 
 
2.3 FTIR AS AN ALTERNATIVE FOR TECHNOLOGICAL INNOVATION IN HEALTHCARE 
 
FTIR is a technique that allows the detection of biochemical changes, even if discrete, related to a 
pathological state, as it analyzes all the molecules present in the sample rapidly and simultaneously (SCOTT et 
al., 2010; SIMSEK OZEK et al., 2016; XIANG et al., 2010).  
When a cell, tissue or biological fluid is traversed by an infrared radiation beam, an interaction between 
this radiation and the chemical bonds of the components of the biological sample occurs (SCOTT et al., 2010). 
The intensities of the FTIR spectra can provide quantitative information, whereas the frequencies reveal 
qualitative characteristics about the nature of the sample (MOVASAGHI; REHMAN; UR REHMAN, 2008; 
ORPHANOU, 2015; SCOTT et al., 2010). The result of the interaction between the radiation and the sample 
produces a spectrum consisting of bands, which represent the vibrations of the chemical bonds of the compounds 
contained therein (MOVASAGHI; REHMAN; UR REHMAN, 2008; ORPHANOU, 2015). The FTIR spectrum is the sum 
of all these contributions, including changes in cells, tissues or fluids that occur in pathological processes. 
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Consequently, the probability of two samples having the same spectrum is quite small, which makes it a 
molecular "fingerprint" of it. In addition, changes in a sample’s "fingerprint" due to a pathological state make it 
possible to detect and follow the disease process (MOVASAGHI; REHMAN; UR REHMAN, 2008; ORPHANOU, 2015; 
SCOTT et al., 2010; XIANG et al., 2010). 
Recently, FTIR has emerged as one of the main tools for biomedical applications and has made 
significant progress in the field of clinical evaluation because it is relatively simple, low cost, noninvasive, 
nondestructive, reproducible and uses small amounts of sample with minimal preparation (MIKKONEN et al., 
2016; MOVASAGHI; REHMAN; UR REHMAN, 2008; SIMSEK OZEK et al., 2016; XIANG et al., 2010). Numerous 
diseases have already been detected by applying FTIR in serum and plasma samples such as rheumatoid arthritis 
(LECHOWICZ et al., 2016), heart disease (HAAS et al., 2010), dyslipidemia (SATO et al., 2010), leukemia (SHENG 
et al., 2013) and bladder (OLLESCH et al., 2014), ovary (GAJJAR et al., 2013; OWENS et al., 2014) and lung 
cancer (KAZNOWSKA et al., 2018). In CRC cases, the investigations have focused on the discrimination of 
malignant tissues from healthy tissues using preponderantly solid biopsies through the FTIR microspectroscopy 
technique (ARGOV et al., 2002;  KAZNOWSKA et al., 2017; KHANMOHAMMADI et al., 2009; KHANMOHAMMADI et 
al., 2011; LI, Q.-B. et al., 2005; LI, X. et al., 2012; RAMESH et al., 2001; SAHU; SALMAN; MORDECHAI, 2017; 
SALMAN et al., 2001).  
 
3 MATERIALS AND METHODS 
 
3.1 SAMPLING 
 
In this study, plasma samples were collected from 15 healthy patients (control group) and 15 patients 
with CRC (primary cancer), totaling 30 samples. The samples were from a case-control study, where the selection 
predicted patients of any age and gender, diagnosed with colorectal cancer of any histological type. All patients 
came from the Clinical Hospital of Passo Fundo City (Passo Fundo, Rio Grande do Sul, Brazil). The research 
protocol was approved by the Ethics and Research Committee of the University of Santa Cruz do Sul (Protocol No. 
1,796,188). Only the patients who signed Written Informed Consent were included in the study. 
 
3.2 ACQUISITION OF INFRARED SPECTRA BY ATR-FTIR 
 
Plasma samples were diluted in a 1:10 ratio and 3 μl aliquots of the dilutions were homogenized, 
deposited on the reading crystal and dehydrated in air current (60-65 ° C) for 1.5 min. Attenuated Total Reflection 
(ATR-FTIR) analysis was carried out on Spectrum™ 400 FTIR/FT-NIR Spectrometer (Perkin Elmer®). All FTIR 
analyses were performed in triplicate and the spectra were recorded from 650 to 4000 cm-1, with the spectral 
resolution of 4 cm-1 and 8 scanning pulses 
 
3.3 CHEMOMETRIC ANALYSIS 
 
The spectra were normalized by amplitude between 0 and 1 and the mean spectrum of the 30 samples 
obtained using Microsoft Office Excel 2010 software (Microsoft®). The multivariate analysis was performed with 
the triplicates of the samples (n = 90) with the software Pirouette 4.0 (Infometrix®), through partial least squares 
regression-discriminant analysis (PLS-DA) with different types of pre-processing per variable (none, auto-scale and 
mean-center) and per sample [none, 1st derivative (5 points), 2nd derivative (5 points)] and orthogonal signal 
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correction (OSC) amount by leave-one-out cross-validation. The PLS-DA condition that presented the best results 
was selected to proceed with the correlation model and the number of latent variables (LV) was chosen 
considering the first LV with a root square error of cross-validation (RMSECV) lower than 1% (RMSECV ≤ 0.01). 
The calibration set was defined based on the minimum LV number, according to ASTM E1655-05 (ASTM 
INTERNATIONAL, 2012). From the results of the best PLS-DA condition, the samples were separated into two 
classes or groups: control and CRC. They were then organized in crescent order of error and systematically 
separated with 1:1 ratio for the calibration and validation sets, taking care to include the highest and lowest error 
value (independent of the class) in the calibration set, as well as observing so that the calibration and validation 
sets presented a close number of samples of each class. The results for the correlation model were obtained from 
the tests for each sample of the validation set and evaluated through RMSECV, mean square error of prediction 
(RMSEP), coefficient of determination (R2), sensitivity, accuracy and precision as previously described (BERGHOLT 
et al., 2015; BERGHOLT et al., 2016; LIU et al., 2016). Figures for PLS-DA / FTIR models were obtained using the 
Origin 7.0 software (OriginLab Corporation®). 
 
4 RESULTS AND DISCUSSION 
 
Two mean infrared spectra were obtained from the replicates of the 15 samples of both classes (control 
and CRC; Figure 1). The bands of both spectra were identical, with slight absorbance intensity variations. The 
mean spectra presented bands in 3300-3250 cm-1, 3000-2800 cm-1, 1750-1500 cm-1, 1500-1400 cm-1, 1400-
1300 cm-1 and 1300-1050 cm-1. The bands can be assigned to protein vibrations in 3300-3250 cm-1 (νN-H), 
1750-1500 cm-1 (amide I in 1646 cm-1 and amide II in 1539 cm-1) and 1400-1300 cm-1 (amide III); lipid 
vibrations in 3000-2800 cm-1 (νasCH3 and νsCH3) and 1500-1400 cm-1 (δCH2); and to DNA vibrations in 1300-1050 
cm-1 (νasPO2- and νsPO2-), overlapped by carbohydrate ring vibrations in 1200-1000 cm-1, characteristic of 
biological samples as plasma (BAKER et al., 2014; LASCH; NAUMANN, 2015; WOOD, 2016).  
Compared to the control group, the average spectrum of the CRC class showed increased absorption 
intensity in the regions of 3300-3250 cm-1 and 1300-1050 cm-1, attributed to the vibrations of proteins and DNA, 
respectively. It can be assumed that the increase in the intensity observed in these regions is due to the increase 
of DNA in the circulation (cfDNA and ctDNA) due to cell death of cells of the tumor mass (LI et al., 2003; 
SCHWARZENBACH et al., 2008; SCHWARZENBACH; HOON; PANTEL, 2011) and to the increase in the 
concentration or variation of the amino acid and protein profile associated with cancers (GAUTAM et al., 2012; 
MIYAGI et al., 2011; REYNÉS et al., 2011). In order to verify whether these assumptions are true or not, it would 
be necessary to carry out specific analyzes, not included in the scope of this work, but which remain as a 
suggestion for future work. 
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Figure 1. Mean infrared spectra of the control and CRC groups’ plasma samples. 
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In total, 27 PLS-DA conditions were tested. The best PLS-DA was obtained when the 1st derivative, 1 
OSC and none pre-processing per variable were used. With 4 LV, the model presented RMSECV=0.0004, 
RMSEP=0.0001 e r2=1.0000, with P < 0.0001. The model’s accuracy, precision and sensitivity were 100%. 
Correlation graphic (Figure 2, A) present the predicted values for each class. Residuals graphic (Figure 2, B) 
reveals a certain degree of systematic error in the prediction, mainly in the CRC class calibration set. This 
characteristic indicates that there would be need to include non-modeled variance in the first 4 LV and it is 
possibly related to the eventual inclusion of outlier samples. However, since the error was quite low, the predictive 
quality of the model is not impaired.  
It was necessary to use OSC in the data set because, when applied, the predictive quality (measured by 
means of RMSECV and RMSEP) was good in all conditions (data not shown). Besides, the number of LV to 
describe the model was fairly low and the R2 reached 1.0000, demonstrating how well the model can describe 
the observed results, as previously reported by Wold et al. (1998). This is due to the fact that OSC can remove 
noise that disturb the data and non-linear relationships between the spectral data and the attributed classes, 
which made possible to work with the full range of the spectrum in the model (ESTEBAN-DIEZ; GONZÁLEZ-SÁIZ; 
PIZARRO, 2004; SJÖBLOM et al., 1998; WOLD et al., 1998).   
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Figure 2. Correlation graphs between predicted values vs. reference values (A) and residuals vs. reference values 
(B) of the PLS-DA/FTIR model for discrimination of plasma samples from healthy and CRC patients. 
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CS – calibration set; PS – prediction set. Reference values: 1 = CRC cases; 0 = control. 
 
The regression vector (Figure 3) of the model presented its main bands with positive correlation (score > 
0) in 1650-1400 cm-1 and 1400-1200 cm-1. The bands can be attributed to amide I and amide II of proteins in 
1650-1625 cm-1 and 1530-1525 cm-1, respectively; various protein-related vibrations in 1620-1615 cm-1 and 
1500-1350 cm-1; and νasPO2- of DNA in 1250-1200 cm-1 (BAKER et al., 2014; LASCH; NAUMANN, 2015; WOOD, 
2016); demonstrating that the regions of the spectrum that contributed to the class discrimination in the model 
are related to protein and DNA. This result corroborates with those observed for the mean spectra of both groups. 
DNA related (ARMAGHANY et al., 2012; CHENG; SU; QIAN, 2016; SCHWARZENBACH; HOON; PANTEL, 
2011; THIERRY et al., 2014; VOGELSTEIN et al., 1988; WANG et al., 2017) and protein related (ABRAMSON, 
1982; GAUTAM et al., 2012; MIYAGI et al., 2011; REYNÉS et al., 2011) alterations have been described for 
several types of cancers, including CRC. The concentration and the characteristics of the DNA presented in the 
circulation of patients with CRC are different from healthy ones (ARMAGHANY et al., 2012; BETTEGOWDA et al., 
2014; CAO et al., 2018; PEREIRA et al., 2017; SCHWARZENBACH et al., 2008; SPINDLER et al., 2015; UMETANI 
et al., 2006). Likewise, the protein profile is also altered in patients with CRC (BI et al., 2006; MIYAGI et al., 2011; 
MOLINARI et al., 2009; STULÍK et al., 2001). Tomonaga et al. (2004) investigated the protein profile of patients 
with primary CRC and observed a significant variation in the expression of 42 proteins in relation to the control 
group. 
A B 
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Figure 3. PLS-DA/FTIR model regression vector for plasma sample discrimination of healthy and colorectal cancer 
patients. 
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The spectral regions with score greater than zero represent the infrared bands that contributed to class 
discrimination in the PLS-DA model. 
 
Several studies have obtained good results applying FTIR associated to chemometrics in the 
discrimination of healthy and cancer patients (FUJIOKA et al., 2004; HANDS et al., 2016; KHANMOHAMMADI et 
al., 2007; LI et al., 2013, 2012; SHENG et al., 2013). Li et al. (2013) discriminated normal tissues of cancerous 
tissues in gastric biopsies with 100% sensitivity and specificity of 83.3% for cancer and Fujioka et al. (2004) with 
sensitivity and specificity of 96% and 75%, respectively. Hands et al. (2016) obtained excellent sensitivities and 
specificities in the discrimination of serum samples from healthy and cancer patients, metastatic cancer and 
brain tumor, glioma and meningioma, and high-grade glioma and low-grade glioma. 
In the work of Li et al. (2012), colon biopsies of patients with CRC and colitis were discriminated with 
sensitivity of 97.6% and specificity of 70.2%. Argov et al. (2002), using FTIR microscopy, classified biopsies of 
healthy patients, patients with adenomatous polyps and patients with CRC, obtaining 89%, 81%, and 83% 
success rate in the classification, respectively. Other studies have also obtained high sensitivity, specificity and/or 
accuracy in discriminating biopsies of CRC and healthy patients using FTIR microscopy (KHANMOHAMMADI et al., 
2009; LASCHEN; NAUMANN, 1998; SALMAN et al., 2001). However, few studies have used conventional FTIR for 
discriminating samples from patients with CRC and healthy ones. It is also important to highlight that most of the 
studies of FTIR application in the detection of cancer do not use plasma as a sample nor the PLS-DA as 
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chemometric analysis (CHABER et al., 2018; HANDS et al., 2016; KHANMOHAMMADI et al. 2007, 2009, 2011, LI, 
QB et al., 2005, 2013, LI, X. et al., 2012, SHENG et al., 2013). 
 Several CRC screening tests are available, but none is entirely foolproof. Guaiac-based fecal occult blood 
test is simple and cost-effective, but has limited sensitivity. Fecal immunochemical test has a higher sensitivity 
than the guaiac-based test, but is more expensive (BAILEY; AGGARWAL; IMPERIALE, 2016; BÉNARD et al., 2018; 
STRUM, 2016). Colonoscopy has high sensitivity and allows examination of the entire colon and removal of 
polyps; however, it requires bowel preparation and sedation, which decreases patients' acceptability of the exam, 
and can be expensive (STRUM, 2016; SVENSSON et al., 2002; USSUI, 2010; USSUI et al., 2013).  
Our work presented an innovative methodology, in which the differentiation between healthy and 
primary CRC patients was done directly from the plasma, in a non-invasive, fast, simple and low-cost manner, 
through a correlation model (PLS-DA) with spectra obtained by FTIR. The methodology shown herein could be 
easily included in routine laboratory tests, since it requires a very small amount of blood plasma with minimal or 
no sample preparation and does not use reagents or commercial kits. Nevertheless, the presented methodology 
has some limitations. The small number of samples used makes the model less representative, considering the 
heterogeneity of tumors and great individual variation (CRANLEY et al., 2013, CROWLEY et al., 2013, EL 
MESSAOUDI et al., 2016, HEITZER, ULZ, GEIGL, WANG et al., 2017). The model is not static, that is, changes made 
in it, such as adding new samples, will change the model response, even if discreetly. The model can only 
discriminate samples from CRC patients if they already have blood changes related to the disease. In addition, 
the response of the model to samples from patients with other cancers was not evaluated, limiting only to 
primary CRC. Despite these limitations, the methodology presented demonstrates the potential that FTIR 
associated with chemometrics has as complementary analysis for the already available CRC screening and 
diagnostic techniques, which could help improving cancer surveillance and early detection. 
 
5 CONCLUDING REMARKS 
 
The use of the PLS-DA regression with FTIR data showed high accuracy in the discrimination of plasma 
samples from patients with primary CRC and healthy individuals directly from the plasma, demonstrating the 
potential of the techniques as a diagnostic alternative in clinical practice.  
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